(S027) Novel Mechanisms of Adaptive Resistance in Head and Neck Cancer

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Targeted combinatorial therapy with XRT is necessary to overcome adaptive radioresistance. RPPA is a powerful proteomic platform, suggesting alterations in energy metabolism following XRT that are targetable by inhibition of the enzyme glutaminase. Further in vivo experiments with glutaminase inhibition and xenograft models to assess combinatorial efficacy with radiation are warranted.

Vinita Takiar, MD, PhD, Jennifer B. Dennison, PhD, Shreya Mitra, PhD, Dominic Ma, BS, Jack Phan, MD, PhD, Gordon B. Mills, MD, PhD; UT MD Anderson Cancer Center

OBJECTIVE: Locoregional recurrence after definitive radiation therapy (XRT) for head and neck (H&N) cancer is a significant clinical challenge, with many patients failing after combined doses > 100 Gy. Although multimodality treatment is prescribed for many cancers, such treatment algorithms are generally empiric, with no identified molecular basis. The efficacy of XRT is limited by intrinsic and acquired radioresistance. We hypothesize that resistance to XRT is, at least in part, mediated by adaptive signaling events induced by the XRT itself. Using signal transduction to better understand these adaptive responses is therefore crucial to developing rational treatment combinations that increase the therapeutic efficacy of XRT.

MATERIALS AND METHODS: Two representative H&N cell lines (FaDu and HN5) were grown in both two dimensions (2D) and three dimensions (3D) (spheroids suspended in Matrigel). Based on cell survival assays conducted in 2D culture, a dose of 4 Gy (~LD50) was chosen for subsequent experiments. Cells in both 2D and 3D were exposed to either 0 Gy or 4 Gy with a cobalt-60 source and then subjected to high-throughput reverse phase protein analysis (RPPA) to screen for differential protein expression in cells able to survive radiation. As the expression of multiple energy-related metabolites was increased, oxygen consumption rate (OCR), which is a readout of aerobic respiration, was subsequently analyzed using an extracellular flux analyzer. 

RESULTS: Both HN5 and FaDu cells formed intact monolayers in 2D and spheroids in 3D. Radiation of 4 Gy in one fraction resulted in differential expression of multiple signaling pathways in both cell lines, with significant upregulation of multiple components of the mammalian target of rapamycin (mTOR) pathway (P < .05), including pACC, pAMPK, pAkt, and p70S6K-collectively suggesting altered energy metabolism. Glutamine metabolism, regulated by the mTOR pathway, serves as an anaplerotic and limiting reagent for citric acid cycle progression and thus serves as a proof-of-concept pathway. Using a glutaminase-specific inhibitor that prevents the conversion of glutamine to glutamate, we report that the cellular OCR was significantly reduced (P < .001) in the presence of glutamine. However, the OCR was unchanged in the presence of glucose alone, suggesting that glutamine metabolism is indeed the driver of aerobic respiration in these cells.

CONCLUSIONS: Targeted combinatorial therapy with XRT is necessary to overcome adaptive radioresistance. RPPA is a powerful proteomic platform, suggesting alterations in energy metabolism following XRT that are targetable by inhibition of the enzyme glutaminase. Further in vivo experiments with glutaminase inhibition and xenograft models to assess combinatorial efficacy with radiation are warranted.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content